Physician

Thomas R. Vidic, M.D.

According to 2025 Medicare claims, Thomas Vidic, M.D. (NPI: 1265437404) practices neurology in the Elkhart-Goshen, IN market, with the plurality of this provider's patient population coming from Elkhart, IN. This provider's primary affiliated billing organization is PRIVIA MEDICAL GROUP INDIANA, LLC (NPI: 1013912286; TIN: 351911857) and primary practice location at 46514-2066. Vidic is affiliated with the CHA ACO, LLC (ACO ID: A2207) and PRIVIA QUALITY NETWORK - I LLC (ACO ID: A5533), participating under the MSSP model.

Vidic's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 476 traditional Medicare patients, billed 12,745 HCPCS/CPT codes, and received $185,190 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 4,849 prescription claims across 638 beneficiaries totaling $1,160,236 in drug costs, led by Fycompa (Perampanel). 2022 DME data shows 57 claims. Open Payments data shows 180 records totaling $3,658. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has fallen sharply in recent years, from $228,444 to $185,190. Concurrently, Part D prescription costs have changed little. In contrast, DME billing represents a smaller volume and fell sharply in recent years, from $5,041 to $2,383.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	843	13,617	$228,444
2016	772	14,568	$213,440
2017	724	15,737	$266,315
2018	732	17,838	$377,159
2019	637	22,597	$507,286
2020	630	19,120	$497,979
2021	627	21,087	$549,945
2022	606	14,695	$233,608
2023	537	13,165	$190,305
2024	476	12,745	$185,190

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	573	5,636	$1,528,703
2016	574	5,796	$1,574,390
2017	621	6,309	$1,635,511
2018	648	6,407	$1,670,434
2019	610	5,514	$1,597,604
2020	615	5,277	$1,601,662
2021	635	5,247	$1,612,521
2022	619	4,976	$1,212,335
2023	648	4,764	$1,499,597
2024	638	4,849	$1,160,236

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	16	$635
2016	N/R	37	$1,049
2017	N/R	11	$183
2018	N/R	14	$198
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	58	$1,388
2022	N/R	57	$903
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	128	178	$112
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	316	610	$84
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	368	809	$11
36415	Insertion of needle into vein for collection of blood sample	99	117	$9
96127	Assessment of emotional or behavioral problems	92	94	$3

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Fycompa	Perampanel	111	3,587	$153,091
Vumerity	Diroximel Fumarate	12	360	$120,305
Betaseron	Interferon Beta-1b	12	336	$114,527
Austedo	Deutetrabenazine	16	480	$108,480
Rufinamide	Rufinamide	34	1,086	$83,158

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	180	$3,658	Celgene Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Thomas R. Vidic, M.D.?

Tedicare shows public-source Medicare data for Thomas R. Vidic, M.D. (NPI 1265437404), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Thomas R. Vidic, M.D. have ACO affiliation data?

Thomas R. Vidic, M.D. is shown with ACO affiliation data for CHA ACO, LLC (MSSP, ACO ID A2207) and PRIVIA QUALITY NETWORK - I LLC (MSSP, ACO ID A5533).

What billing organization is linked to Thomas R. Vidic, M.D.?

Thomas R. Vidic, M.D. is linked to PRIVIA MEDICAL GROUP INDIANA, LLC (billing NPI 1013912286) in the available physician profile data.

Does Thomas R. Vidic, M.D. have Open Payments data?

Thomas R. Vidic, M.D. has 180 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.